{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:08:40Z","timestamp":1776276520373,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Celltrion Healthcare Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40261-020-00907-5","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T07:02:48Z","timestamp":1587625368000},"page":"541-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-2276","authenticated-orcid":false,"given":"Tae-Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-7355","authenticated-orcid":false,"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-8034","authenticated-orcid":false,"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-3437","authenticated-orcid":false,"given":"Yeong Wook","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-393X","authenticated-orcid":false,"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-3249","authenticated-orcid":false,"given":"SooKyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-4708","authenticated-orcid":false,"given":"Young Nam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-4008","authenticated-orcid":false,"given":"Dae Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"907_CR1","unstructured":"European Medicines Agency. Inflectra Summary of Product Characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inflectra-epar-product-information_en.pdf. Accessed 12 Sept 2019."},{"key":"907_CR2","unstructured":"European Medicines Agency. Remsima Summary of Product Characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf. Accessed 12 Sept 2019."},{"key":"907_CR3","unstructured":"US Food and Drug Administration. Inflectra Prescribing Information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125544s009lbl.pdf. Accessed 12 Sept 2019."},{"key":"907_CR4","unstructured":"Generics and Biosimilars Initiative. Biosimilar monoclonal antibody approved in Korea. 2012. https:\/\/www.gabionline.net\/Biosimilars\/News\/Biosimilar-monoclonal-antibody-approved-in-Korea. Accessed 21 Aug 2019."},{"key":"907_CR5","unstructured":"European Medicines Agency. Remicade Summary of Product Characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 12 Sept 2019."},{"key":"907_CR6","unstructured":"US Food and Drug Administration. Remicade Prescribing Information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103772s5385lbl.pdf. Accessed 12 Sept 2019."},{"issue":"Suppl 1","key":"907_CR7","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1586\/1744666X.2015.1090313","volume":"11","author":"L Gulacsi","year":"2015","unstructured":"Gulacsi L, Brodszky V, Baji P, Kim H, Kim SY, Cho YY, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015;11(Suppl 1):S43\u2013S52.","journal-title":"Expert Rev Clin Immunol"},{"key":"907_CR8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2147\/DDDT.S138515","volume":"11","author":"A Becciolini","year":"2017","unstructured":"Becciolini A, Raimondo MG, Crotti C, Agape E, Biggioggero M, Favalli EG. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Des Dev Ther. 2017;11:1969\u201378.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"907_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/conmed-2017-100005","volume":"1","author":"V Azevedo","year":"2017","unstructured":"Azevedo V, D\u00f6rner T, Strohal R, Isaacs J, Casta\u00f1eda-Hern\u00e1ndez G, Gon\u00e7alves J, et al. Biosimilars: considerations for clinical practice. Consid Med. 2017;1(1):13\u20138.","journal-title":"Consid Med"},{"issue":"5","key":"907_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","volume":"85","author":"M Scherlinger","year":"2018","unstructured":"Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet ME, Bannwarth B, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Jt Bone Spine. 2018;85(5):561\u20137.","journal-title":"Jt Bone Spine"},{"issue":"5","key":"907_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","volume":"32","author":"LE Kristensen","year":"2018","unstructured":"Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32(5):397\u2013404.","journal-title":"BioDrugs"},{"key":"907_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","volume":"18","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:82.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"907_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","volume":"25","author":"T Takeuchi","year":"2015","unstructured":"Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25(6):817\u201324.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"907_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"907_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis"},{"key":"907_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","volume":"18","author":"W Park","year":"2016","unstructured":"Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"907_CR17","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1007\/s10198-014-0593-5","volume":"15","author":"P Baji","year":"2014","unstructured":"Baji P, Pentek M, Szanto S, Geher P, Gulacsi L, Balogh O, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014;15(Suppl 1):S45\u2013S52.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"907_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"907_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Urena S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"907_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","volume":"27","author":"Y Tanaka","year":"2017","unstructured":"Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237\u201345.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"907_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/joim.12880","volume":"285","author":"GL Goll","year":"2019","unstructured":"Goll GL, Jorgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653\u201369.","journal-title":"J Intern Med"},{"issue":"1","key":"907_CR22","first-page":"55","volume":"37","author":"E Nikiphorou","year":"2019","unstructured":"Nikiphorou E, Hannonen P, Asikainen J, Borodina J, Kokko A, Paalanen K, et al. Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care. Clin Exp Rheumatol. 2019;37(1):55\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"907_CR23","doi-asserted-by":"publisher","first-page":"A729","DOI":"10.1136\/annrheumdis-2018-214530","volume":"78","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Christensen R, Moosavi S, Selema P, Guilatco R, Fowler H, et al. Real-world safety data from patients with rheumatic diseases treated with CT-P13, an infliximab biosimilar: an interim analysis from an observtional study [EULAR 2019 Congress abstract FRI0122]. Ann Rheum Dis. 2019;78:A729.","journal-title":"Ann Rheum Dis"},{"key":"907_CR24","first-page":"A718","volume":"78","author":"K Baek","year":"2019","unstructured":"Baek K, Lee YJ, Lee S, Kim H, Lee S, Park JE, et al. A large real world, long term safety study of patients with inflammatory rheumatic diseases treated with infliximab biosimilar (CT-P13): pooled analysis of four global post-marketing studies [EULAR Congress 2019 abstract FRI0104]. Ann Rheum Dis. 2019;78:A718.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"907_CR25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.55563\/clinexprheumatol\/z0va6o","volume":"38","author":"HA Kim","year":"2020","unstructured":"Kim HA, Lee E, Lee SK, Park YB, Lee YN, Kang HJ, et al. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol. 2020;38(2):267\u201374.","journal-title":"Clin Exp Rheumatol"},{"key":"907_CR26","first-page":"70","volume":"2018","author":"HA Kim","year":"2018","unstructured":"Kim HA, Lee EY, Lee SK, Park YB, Lee YN, Kang H, et al. Retention rate and safety data of biosimilar CT-P13 in patients with rheumatoid arthritis: data from the Korean College of Rheumatology Biologics registry, [2018 ACR\/ARHP Annual Meeting abstract 2543]. Arthritis Rheumatol. 2018;2018:70.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"907_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"907_CR28","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"4","key":"907_CR29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken). 2016;68(4):432\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"907_CR30","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3899\/jrheum.111125","volume":"39","author":"F Iannone","year":"2012","unstructured":"Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39(6):1179\u201384.","journal-title":"J Rheumatol"},{"issue":"6","key":"907_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/acr.23090","volume":"69","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res (Hoboken). 2017;69(6):867\u201374.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"907_CR32","doi-asserted-by":"publisher","first-page":"R72","DOI":"10.1186\/ar1941","volume":"8","author":"L Carmona","year":"2006","unstructured":"Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8(3):R72.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"907_CR33","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3346\/jkms.2014.29.9.1205","volume":"29","author":"JH Kang","year":"2014","unstructured":"Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ, et al. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci. 2014;29(9):1205\u201311.","journal-title":"J Korean Med Sci"},{"issue":"6","key":"907_CR34","first-page":"958","volume":"27","author":"K Pavelka","year":"2009","unstructured":"Pavelka K, Forejtova S, Stolfa J, Chroust K, Buresova L, Mann H, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27(6):958\u201363.","journal-title":"Clin Exp Rheumatol."},{"issue":"2","key":"907_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"907_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","volume":"74","author":"E Lie","year":"2015","unstructured":"Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandstrom T, Askling J, Jacobsson LT. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis. 2015;74(6):970\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"907_CR37","doi-asserted-by":"publisher","first-page":"e0216624","DOI":"10.1371\/journal.pone.0216624","volume":"14","author":"K Ebina","year":"2019","unstructured":"Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis\u2014the ANSWER cohort study. PLoS One. 2019;14(5):e0216624.","journal-title":"PLoS One"},{"issue":"1","key":"907_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22\u201332.","journal-title":"Arthritis Rheum"},{"issue":"sup1","key":"907_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonzalez-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11\u201334.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"907_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apt.14997","volume":"49","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49(1):31\u201340.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"907_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/MEG.0000000000000049","volume":"26","author":"A Krajcovicova","year":"2014","unstructured":"Krajcovicova A, Hlavaty T, Zelinkova Z, Letkovsky J, Huorka M. Delayed hypersensitivity reaction after initial dose of infliximab: a case report. Eur J Gastroenterol Hepatol. 2014;26(4):485\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"907_CR42","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","volume":"9","author":"L Lichtenstein","year":"2015","unstructured":"Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806\u201315.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"907_CR43","first-page":"1955","volume":"31","author":"N Mohan","year":"2004","unstructured":"Mohan N, Edwards ET, Cupps TR, Slifman N, Lee J-H, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31(10):1955\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"907_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/s10165-009-0232-7","volume":"20","author":"K Fujikawa","year":"2010","unstructured":"Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri S, Aramaki T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20(1):86\u20139.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"907_CR45","first-page":"2287","volume":"30","author":"SJ Jarrett","year":"2003","unstructured":"Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30(10):2287.","journal-title":"J Rheumatol"},{"issue":"8","key":"907_CR46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","volume":"87","author":"O Sokumbi","year":"2012","unstructured":"Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-\u03b1 inhibitors. Mayo Clin Proc. 2012;87(8):739\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"907_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007;86(4):242\u201351.","journal-title":"Medicine"},{"issue":"3","key":"907_CR48","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2018.01.061","volume":"155","author":"JMF Chebli","year":"2018","unstructured":"Chebli JMF, de Oliveira MB, da Rocha Ribeiro TC. An unusual cause of skin rash in Crohn's disease. Gastroenterology. 2018;155(3):618\u201320.","journal-title":"Gastroenterology"},{"issue":"10","key":"907_CR49","first-page":"1885","volume":"31","author":"L Guillevin","year":"2004","unstructured":"Guillevin L, Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol. 2004;31(10):1885\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"907_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","volume":"18","author":"P Sarzi-Puttini","year":"2019","unstructured":"Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A, Atzeni F. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18(6):583\u201392.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"907_CR51","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.semarthrit.2017.08.007","volume":"47","author":"MY Lee","year":"2018","unstructured":"Lee MY, Shin JY, Park SY, Kim D, Cha HS, Lee EK. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum. 2018;47(4):485\u201391.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00907-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T03:12:14Z","timestamp":1666408334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00907-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00907-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"23 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Ajou University Hospital Institutional Review Board, AJIRB-MED-MDB-17-449; Chonnam National University Hospital Institutional Review Board, CNUH-2018-030; Hanyang University Hospital Institutional Review Board, HYU 2017-12-037; Inha University Hospital Institutional Review Board, INHAUH201712010; Seoul National University College of Medicine\/Seoul National University Hospital Institutional Review Board, H-1801-047-914) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants"}},{"value":"For this type of retrospective analysis, formal informed consent was not required, in accordance with Article 16 of the Bioethics and Safety Act of the Republic of Korea.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"T-HK, S-SL and YWS report no conflicts of interest. WP received consulting fees from Celltrion Healthcare. C-HS received consulting fees (<\u2009$10,000) from CELLTRION. SKK and YNL are employees of Celltrion Healthcare and own stock\/stock options for Celltrion Healthcare. DHY received fees from Celltrion for grants, consulting, advisory board meetings, speakers\u2019 bureau and lectures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}